Nisa Investment Advisors LLC increased its stake in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 22.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 18,770 shares of the medical research company’s stock after buying an additional 3,451 shares during the period. Nisa Investment Advisors LLC’s holdings in Natera were worth $7,758,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Natera during the 2nd quarter worth approximately $2,962,770,000. Arrowstreet Capital Limited Partnership raised its holdings in shares of Natera by 1.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,191,732 shares of the medical research company’s stock worth $238,334,000 after purchasing an additional 11,793 shares during the period. Maverick Capital Ltd. raised its holdings in shares of Natera by 24.1% in the 1st quarter. Maverick Capital Ltd. now owns 1,171,633 shares of the medical research company’s stock worth $234,315,000 after purchasing an additional 227,605 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Natera by 10.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 833,376 shares of the medical research company’s stock worth $226,220,000 after purchasing an additional 80,440 shares during the period. Finally, Bank of America Corp DE purchased a new position in Natera in the second quarter valued at approximately $199,960,000. Institutional investors own 99.90% of the company’s stock.
Insider Buying and Selling
In other news, insider Solomon Moshkevich sold 15,160 shares of Natera stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $326.89, for a total value of $4,955,652.40. Following the completion of the transaction, the insider directly owned 110,859 shares in the company, valued at approximately $36,238,698.51. The trade was a 12.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 6,517 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $321.53, for a total value of $2,095,411.01. Following the sale, the insider owned 197,257 shares in the company, valued at approximately $63,424,043.21. The trade was a 3.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 52,985 shares of company stock valued at $16,119,137 in the last ninety days. 5.05% of the stock is owned by company insiders.
Analysts Set New Price Targets
NTRA has been the subject of several research reports. Guggenheim increased their price objective on Natera from $360.00 to $475.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Wells Fargo & Company raised their target price on Natera from $220.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Canaccord Genuity Group boosted their target price on Natera from $375.00 to $500.00 and gave the company a “buy” rating in a research note on Monday. UBS Group upped their price target on Natera from $290.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, September 9th. Finally, JPMorgan Chase & Co. increased their price target on Natera from $360.00 to $460.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 14th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $379.20.
Get Our Latest Report on Natera
Natera Stock Down 2.9%
NTRA opened at $401.37 on Friday. Natera, Inc. has a 12 month low of $181.00 and a 12 month high of $437.41. The company has a 50 day moving average of $365.45 and a 200 day moving average of $281.52.
Natera (NASDAQ:NTRA – Get Free Report) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The business had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.74) EPS. As a group, equities analysts forecast that Natera, Inc. will post -1.05 earnings per share for the current fiscal year.
About Natera
Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.
In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.
Read More
- Five stocks we like better than Natera
- Is Texas Instruments Setting Up for Its Next Big Breakout?
- Pegasystems’ Q3 Miss Exposed the Problem Standing Between AI and Cash Flow
- Lam Research’s Earnings Beat Wasn’t the Real Story—Its 2027 Outlook Was
- Tesla’s Flying-Car Hype Hits an Earnings Reality Check
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
